(ARDS) $0.84 --BIG Phase 3 data in December ...Very low valuation of $17 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.